Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 5/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 9/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908934 | 0.86 | FGFR1 (0.49) | FGFR1FGFR2FGFR3IDH1PHGDH | |
| SCHEMBL18824232 | 0.81 | POLB (0.48) | FGFR1FGFR2FGFR3XDH | |
| SCHEMBL3623549 | 0.78 | XDH (0.53) | XDH | |
| SCHEMBL22199092 | 0.77 | IDH1 (0.51) | FGFR1FGFR2FGFR3IDH1PHGDH | |
| SCHEMBL17604498 | 0.76 | IDH1 (0.53) | FGFR1FGFR2FGFR3IDH1 | |
| SCHEMBL27247382 | 0.74 | IDH1 (0.40) | FGFR1FGFR2FGFR3IDH1CNR2 | |
| SCHEMBL30920707 | 0.74 | IDH1 (0.40) | FGFR1FGFR2FGFR3IDH1CNR2 | |
| SCHEMBL21549749 | 0.74 | IDH1 (0.60) | IDH1 | |
| SCHEMBL17604497 | 0.74 | IDH1 (0.49) | FGFR1FGFR2FGFR3IDH1 | |
| SCHEMBL21662632 | 0.74 | SCN9A (0.49) | CNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | FGFR1 239/4885FGFR2 501/4885FGFR3 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.